Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13701MR)

This product GTTS-WQ13701MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13701MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13997MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ15963MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ1677MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACZ885
GTTS-WQ9644MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ1153MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABP 215
GTTS-WQ3513MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ13494MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ7884MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-249320
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW